Nature's Sunshine Reports Third Quarter 2026 Results
Asia sales fell 14.9% year over year, while nine-month operating cash flow declined to $9.7 million from $25.4 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nature’s Sunshine Products (Nasdaq: NATR) reported lower third-quarter 2026 sales and earnings and cut its full-year sales and adjusted earnings outlook. Sales fell 9% to $116.6 million from $128.3 million, or 7% excluding currency effects. GAAP earnings attributable to common shareholders fell to $1.9 million, or $0.11 per diluted share, from $5.3 million, or $0.30. Adjusted EBITDA, a non-GAAP earnings measure, declined to $11.1 million from $15.2 million.
The company now expects 2026 sales of $460–$470 million, down from $490–$500 million, and adjusted EBITDA of $44–$48 million, down from $48–$52 million. It cited a stronger U.S. dollar and challenges in China. Nine-month operating cash flow fell to $9.7 million from $25.4 million. Cash and cash equivalents totaled $89.4 million at September 30, with zero debt.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointSeptember 30 liquidity included $89.4 million in cash and cash equivalents and zero debt.
- Moderate pointNine-month operating income rose to $20.308 million from $19.421 million a year earlier.
- Minor pointThird-quarter SG&A fell to $42.3 million from $45.7 million, although its sales share rose to 36.3% from 35.6%.
- Minor pointLatin America and Other third-quarter sales rose 3.4% to $5.462 million, but fell 0.1% excluding currency effects.
- Minor pointNine-month sales increased to $356.480 million from $356.337 million a year earlier.
2 minor points
- Minor pointThird-quarter income tax provision decreased to $3.478 million from $4.137 million a year earlier.
- Minor pointManagement has begun rebuilding China’s consultant leadership base and continues investing in its Digital business.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 sales guidance cut to $460–$470 million from $490–$500 million.
- Moderate pointThird-quarter sales fell 9% to $116.6 million year over year, down 7% excluding currency effects.
- Moderate pointThird-quarter common-shareholder earnings fell to $1.9 million, or $0.11 diluted EPS, from $5.3 million, or $0.30.
- Moderate pointThird-quarter adjusted EBITDA fell to $11.1 million from $15.2 million a year earlier.
- Moderate pointNine-month operating cash flow fell to $9.7 million from $25.4 million a year earlier.
13 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 adjusted EBITDA guidance cut to $44–$48 million from $48–$52 million.
- Minor pointAsia third-quarter sales fell 14.9% to $55.056 million, down 11.2% excluding currency effects.
- Minor pointNorth America third-quarter sales fell 6.1% to $34.009 million, down 6.0% excluding currency effects.
- Minor pointEurope third-quarter sales fell 0.1% to $22.076 million, although they rose 0.9% excluding currency effects.
- Minor pointThird-quarter gross margin decreased to 72.9% from 73.3% a year earlier.
- Minor pointThird-quarter volume incentives rose to 32.0% of sales from 30.7% a year earlier.
- Minor pointThird-quarter operating income fell to $5.3 million, or 4.5% of sales, from $9.0 million, or 7.0%.
- Minor pointThird-quarter other income, net, decreased to $86,000 from $697,000 a year earlier.
- Minor pointNine-month capital expenditures increased to $6.8 million from $4.1 million a year earlier.
- Minor pointCash and cash equivalents fell to $89.377 million at September 30 from $93.891 million at December 31, 2025.
- Minor pointNine-month common-shareholder earnings fell to $10.546 million, or $0.59 diluted EPS, from $15.414 million, or $0.83.
- Minor pointNine-month adjusted EBITDA decreased to $37.047 million from $37.421 million a year earlier.
- Minor pointManagement said China operational disruptions affected its consultant leadership base more than anticipated.
News Explained
During the
Details
Market move: NATR -14.20% vs previous close. 3Q26 earnings report
On Nov 4, the day this news came out, the latest delayed price for NATR is 14.20% below the previous close. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $11.02.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Net sales
- $116.6 million vs. $128.3 million
- Q3 2026 vs. year-ago quarter; down 9%
- Gross profit margin
- 72.9% vs. 73.3%
- Q3 2026 vs. year-ago quarter
- GAAP net income attributable to common shareholders
- $1.9 million vs. $5.3 million
- Q3 2026 vs. year-ago quarter
- Diluted EPS
- $0.11 vs. $0.30
- Q3 2026 vs. year-ago quarter
- Adjusted EBITDA
- $11.1 million vs. $15.2 million
- Q3 2026 vs. year-ago quarter
- 2026 net sales guidance
- $460–$470 million; prior range $490–$500 million
- Full-year 2026 outlook
- 2026 adjusted EBITDA guidance
- $44–$48 million; prior range $48–$52 million
- Full-year 2026 outlook
Previous Earnings Reports
-
Q2 had reduced full-year sales guidance to $490–$500 million and adjusted EBITDA to $48–$52 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gaap financial
adjusted ebitda financial
constant currency financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEHI, Utah, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR) ("Nature’s Sunshine"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Summary vs. Same Year-Ago Quarter
- Net sales were down
9% to$116.6 million compared to$128.3 million (down7% in constant currency). - Gross profit margin decreased 42 basis points to
72.9% compared to73.3% . - GAAP net income attributable to common shareholders was
$1.9 million , or$0.11 per diluted common share, compared to$5.3 million , or$0.30 per diluted common share. - Adjusted EBITDA was
$11.1 million compared to$15.2 million .
Management Commentary
"Our third-quarter results were disappointing and fell short of our expectations,” said Ken Romanzi, CEO of Nature’s Sunshine. “We faced several challenges in our business, particularly in China and in our Digital business. In China, operational disruptions have had a more significant impact on our consultant leadership base than we initially anticipated which we have already begun rebuilding. Further, following several quarters of exceptional growth in our Digital business, we are continuing to invest in this critical part of our portfolio to position it for the next phase of growth."
"While our third quarter performance was far from our expectations, our confidence in the long-term potential of Nature's Sunshine remains strong."
Third Quarter 2026 Financial Results
| Net Sales by Operating Segment (Amounts in Thousands) | ||||||||||||||||
| Three Months Ended September 30, | 2026 | 2025 | Percent Change | Impact of Currency Exchange | Percent Change Excluding Impact of Currency | |||||||||||
| Asia | $ | 55,056 | $ | 64,725 | (14.9)% | $ | (2,437 | ) | (11.2)% | |||||||
| Europe | 22,076 | 22,107 | (0.1 | ) | (227 | ) | 0.9 | |||||||||
| North America | 34,009 | 36,224 | (6.1 | ) | (42 | ) | (6.0 | ) | ||||||||
| Latin America and Other | 5,462 | 5,283 | 3.4 | 182 | (0.1 | ) | ||||||||||
| $ | 116,603 | $ | 128,339 | (9.1)% | $ | (2,524 | ) | (7.2)% | ||||||||
Net sales in the third quarter of 2026 decreased
Gross profit margin in the third quarter of 2026 decreased to
Volume incentives as a percentage of net sales were
Selling, general and administrative expenses ("SG&A") in the third quarter of 2026 were
Operating income in the third quarter of 2026 decreased to
Other income (expense), net, in the third quarter of 2026 was
GAAP net income attributable to common shareholders decreased to
Adjusted EBITDA in the third quarter of 2026 decreased to
Balance Sheet and Cash Flow
Net cash provided by operating activities was
Outlook
Reflecting the impact of a stronger U.S. dollar and recent challenges in the China market, Nature's Sunshine now expects full year 2026 net sales to range between
Conference Call
The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its third quarter of 2026 results.
Date: Wednesday, November 4, 2026
Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 30563
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.
The conference call will be broadcast live and available for replay here and via the Events section of the Nature’s Sunshine website here.
A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through Wednesday, November 18, 2026.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1130563
About Nature’s Sunshine Products
Nature’s Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature’s Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements regarding the Company’s future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:
- failure to comply with laws and regulations relating to trade restrictions and export controls;
- laws and regulations regarding direct selling that may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
- corrective or remedial actions involving independent sales representatives that may disrupt their sales organizations or adversely affect our sales and results of operations;
- current and potential future extensive government regulations to which the Company’s products, business practices and manufacturing activities are subject;
- registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
- legal challenges to the Company’s direct selling program or to the classification of its independent consultants;
- failure of the Company’s independent consultants to comply with advertising laws;
- product liability claims;
- impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
- the Company’s ability to attract and retain independent consultants;
- the loss of one or more key independent consultants who have a significant sales network;
- potential for liability relating to the Company’s full ownership of its China business;
- the effect of fluctuating foreign exchange rates;
- liabilities and obligations arising from improper activity by the Company’s independent consultants;
- changes to the Company’s independent consultant compensation plans;
- geopolitical issues, conflicts or other global events;
- negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s consumers to purchase products;
- risks associated with the manufacturing of the Company’s products;
- supply chain disruptions, manufacturing interruptions or delays or the failure to accurately forecast consumer demand;
- failure to timely and effectively obtain shipments of products from our suppliers and deliver products to our independent consultants and consumers;
- uncertainties relating to the application of transfer pricing, duties, value-added taxes and other tax regulations, and changes thereto;
- failure to maintain an effective system of internal controls over financial reporting;
- cybersecurity threats and exposure to data loss;
- the storage, processing and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
- reliance on information technology infrastructure; and
- the sufficiency of trademarks and other intellectual property rights.
These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption “Risk Factors” in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.
All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.
Non-GAAP Financial Measures
We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.
We believe that these non-GAAP measures provide investors with greater transparency to evaluate operational activities and financial results and facilitate consistent comparisons to the historical operating performance of prior periods. We utilize these non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our operating performance and ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.
Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature’s Sunshine Products’ performance in relation to other companies. We have included a reconciliation of net income, the most comparable GAAP measure, to adjusted EBITDA. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.
Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period's net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.
We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
With respect to our adjusted EBITDA outlook for the full year 2026, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including stock based compensation and other potential adjustments. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.
Investor Relations:
Gateway Group, Inc.
Cody Slach
1-949-574-3860
NATR@gateway-grp.com
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts in thousands, except per share information) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net sales | $ | 116,603 | $ | 128,339 | $ | 356,480 | $ | 356,337 | |||||||
| Cost of sales | 31,641 | 34,290 | 95,367 | 98,392 | |||||||||||
| Gross profit | 84,962 | 94,049 | 261,113 | 257,945 | |||||||||||
| Operating expenses: | |||||||||||||||
| Volume incentives | 37,365 | 39,348 | 110,075 | 108,552 | |||||||||||
| Selling, general and administrative | 42,315 | 45,726 | 130,730 | 129,972 | |||||||||||
| Operating income | 5,282 | 8,975 | 20,308 | 19,421 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest and other income, net | 101 | 51 | 336 | 524 | |||||||||||
| Interest expense | (30 | ) | (26 | ) | (118 | ) | (71 | ) | |||||||
| Foreign exchange gains (losses), net | 15 | 672 | (1,637 | ) | 4,451 | ||||||||||
| 86 | 697 | (1,419 | ) | 4,904 | |||||||||||
| Income before provision for income taxes | 5,368 | 9,672 | 18,889 | 24,325 | |||||||||||
| Provision for income taxes | 3,478 | 4,137 | 8,343 | 8,387 | |||||||||||
| Net income | 1,890 | 5,535 | 10,546 | 15,938 | |||||||||||
| Net income attributable to noncontrolling interests | — | 201 | — | 524 | |||||||||||
| Net income attributable to common shareholders | $ | 1,890 | $ | 5,334 | $ | 10,546 | $ | 15,414 | |||||||
| Basic and diluted net income per common share: | |||||||||||||||
| Basic earnings per share attributable to common shareholders | $ | 0.11 | $ | 0.30 | $ | 0.60 | $ | 0.85 | |||||||
| Diluted earnings per share attributable to common shareholders | $ | 0.11 | $ | 0.30 | $ | 0.59 | $ | 0.83 | |||||||
| Weighted average basic common shares outstanding | 17,519 | 17,638 | 17,553 | 18,174 | |||||||||||
| Weighted average diluted common shares outstanding | 17,870 | 18,034 | 17,906 | 18,563 | |||||||||||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) (Unaudited) | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 89,377 | $ | 93,891 | |||
| Accounts receivable, net of allowance for doubtful accounts of | 18,325 | 8,602 | |||||
| Inventories | 71,289 | 68,312 | |||||
| Prepaid expenses and other | 9,394 | 8,040 | |||||
| Total current assets | 188,385 | 178,845 | |||||
| Property, plant and equipment, net | 29,701 | 32,915 | |||||
| Operating lease right-of-use assets | 19,023 | 17,600 | |||||
| Restricted investment securities - trading | 1,225 | 1,132 | |||||
| Deferred income tax assets | 19,328 | 20,068 | |||||
| Other assets | 10,570 | 10,586 | |||||
| Total assets | $ | 268,232 | $ | 261,146 | |||
| Liabilities and Shareholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 8,151 | $ | 8,021 | |||
| Accrued volume incentives and service fees | 25,758 | 22,624 | |||||
| Accrued liabilities | 27,523 | 34,080 | |||||
| Deferred revenue | 5,910 | 5,840 | |||||
| Income taxes payable | 1,577 | 4,703 | |||||
| Current portion of operating lease liabilities | 4,569 | 3,270 | |||||
| Total current liabilities | 73,488 | 78,538 | |||||
| Liability related to unrecognized tax benefits | 1,748 | 428 | |||||
| Long-term portion of operating lease liabilities | 16,459 | 15,630 | |||||
| Deferred compensation payable | 1,225 | 1,132 | |||||
| Deferred income tax liabilities | 1,069 | 954 | |||||
| Other liabilities | 2,561 | 2,911 | |||||
| Total liabilities | 96,550 | 99,593 | |||||
| Shareholders’ equity: | |||||||
| Common stock, no par value, 50,000 shares authorized, 17,386 and 17,508 shares issued and outstanding, respectively | 99,179 | 102,192 | |||||
| Retained earnings | 87,474 | 76,928 | |||||
| Accumulated other comprehensive loss | (14,971 | ) | (17,567 | ) | |||
| Total shareholders’ equity | 171,682 | 161,553 | |||||
| Total liabilities and shareholders’ equity | $ | 268,232 | $ | 261,146 | |||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands) (Unaudited) | ||||||||
| Nine Months Ended September 30, | 2026 | 2025 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 10,546 | $ | 15,938 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 9,735 | 10,538 | ||||||
| Non-cash lease expense | 3,123 | 3,792 | ||||||
| Share-based compensation expense | 5,585 | 4,223 | ||||||
| Deferred income taxes | 1,012 | (2,104 | ) | |||||
| Purchase of trading investment securities | (220 | ) | (94 | ) | ||||
| Proceeds from sale of trading investment securities | 287 | 14 | ||||||
| Realized and unrealized gains on investments | (161 | ) | (112 | ) | ||||
| Foreign exchange (gains) losses | 1,637 | (4,451 | ) | |||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (9,507 | ) | (5,254 | ) | ||||
| Inventories | (2,900 | ) | (6,428 | ) | ||||
| Prepaid expenses and other current assets | (1,334 | ) | (1,323 | ) | ||||
| Other assets | 398 | (465 | ) | |||||
| Accounts payable | 525 | (2,401 | ) | |||||
| Accrued volume incentives and service fees | 2,751 | 4,165 | ||||||
| Accrued liabilities | (7,219 | ) | 5,412 | |||||
| Deferred revenue | (226 | ) | 4,615 | |||||
| Lease liabilities | (2,421 | ) | (3,883 | ) | ||||
| Income taxes payable | (3,286 | ) | 2,814 | |||||
| Liability related to unrecognized tax benefits | 1,320 | 235 | ||||||
| Deferred compensation payable | 94 | 192 | ||||||
| Net cash provided by operating activities | 9,739 | 25,423 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property, plant and equipment | (6,793 | ) | (4,143 | ) | ||||
| Net cash used in investing activities | (6,793 | ) | (4,143 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from revolving credit facility | 30,935 | 1,823 | ||||||
| Principal payments of revolving credit facility | (30,935 | ) | (1,823 | ) | ||||
| Payments related to tax withholding for net-share settled equity awards | (2,502 | ) | (872 | ) | ||||
| Repurchase of common stock | (6,096 | ) | (14,376 | ) | ||||
| Net cash used in financing activities | (8,598 | ) | (15,248 | ) | ||||
| Effect of exchange rates on cash and cash equivalents | 1,138 | 4,822 | ||||||
| Net increase (decrease) in cash and cash equivalents | (4,514 | ) | 10,854 | |||||
| Cash and cash equivalents at the beginning of the period | 93,891 | 84,700 | ||||||
| Cash and cash equivalents at the end of the period | $ | 89,377 | $ | 95,554 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes, net of refunds | $ | 9,457 | $ | 7,699 | ||||
| Cash paid for interest | 118 | 71 | ||||||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA (Amounts in thousands) (Unaudited) | ||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||
| Net income | $ | 1,890 | $ | 5,535 | $ | 10,546 | $ | 15,938 | ||||||
| Adjustments: | ||||||||||||||
| Depreciation and amortization | 3,211 | 3,539 | 9,735 | 10,538 | ||||||||||
| Share-based compensation expense | 1,955 | 1,285 | 5,585 | 4,223 | ||||||||||
| Other (income) expense, net* | (86 | ) | (697 | ) | 1,419 | (4,904 | ) | |||||||
| Provision for income taxes | 3,478 | 4,137 | 8,343 | 8,387 | ||||||||||
| Other adjustments (1) | 689 | 1,386 | 1,419 | 3,239 | ||||||||||
| Adjusted EBITDA | $ | 11,137 | $ | 15,185 | $ | 37,047 | $ | 37,421 | ||||||
| (1) Other adjustments | ||||||||||||||
| Other non-recurring expenses | $ | 689 | $ | 1,386 | $ | 1,419 | $ | 3,239 | ||||||
| Total adjustments | $ | 689 | $ | 1,386 | $ | 1,419 | $ | 3,239 | ||||||
* Other (income) expense, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME and NON-GAAP ADJUSTED EPS (Amounts in thousands) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income | $ | 1,890 | $ | 5,535 | $ | 10,546 | $ | 15,938 | |||||||
| Adjustments: | |||||||||||||||
| Other non-recurring expenses | 689 | 1,386 | 1,419 | 3,239 | |||||||||||
| Tax impact of adjustments | (172 | ) | (347 | ) | (355 | ) | (810 | ) | |||||||
| Total adjustments | 517 | 1,039 | 1,064 | 2,429 | |||||||||||
| Non-GAAP net income | $ | 2,407 | $ | 6,574 | $ | 11,610 | $ | 18,367 | |||||||
| Reported income attributable to common shareholders | $ | 1,890 | $ | 5,334 | $ | 10,546 | $ | 15,414 | |||||||
| Total adjustments | 517 | 1,039 | 1,064 | 2,429 | |||||||||||
| Non-GAAP net income attributable to common shareholders | $ | 2,407 | $ | 6,373 | $ | 11,610 | $ | 17,843 | |||||||
| Basic income per share, as reported | $ | 0.11 | $ | 0.30 | $ | 0.60 | $ | 0.85 | |||||||
| Total adjustments, net of tax | 0.03 | 0.06 | 0.06 | 0.13 | |||||||||||
| Basic income per share, as adjusted | $ | 0.14 | $ | 0.36 | $ | 0.66 | $ | 0.98 | |||||||
| Diluted income per share, as reported | $ | 0.11 | $ | 0.30 | $ | 0.59 | $ | 0.83 | |||||||
| Total adjustments, net of tax | 0.03 | 0.06 | 0.06 | 0.13 | |||||||||||
| Diluted income per share, as adjusted | $ | 0.14 | $ | 0.36 | $ | 0.65 | $ | 0.96 | |||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Nature’s Sunshine’s third-quarter 2026 sales and earnings?
Nature’s Sunshine reported sales of $116.6 million and GAAP earnings attributable to common shareholders of $1.9 million, or $0.11 per diluted share. A year earlier, sales were $128.3 million and common-shareholder earnings were $5.3 million, or $0.30 per diluted share.
What is Nature’s Sunshine’s updated full-year 2026 outlook?
Nature’s Sunshine now expects $460–$470 million in sales and $44–$48 million in adjusted EBITDA for 2026. The previous ranges were $490–$500 million and $48–$52 million, respectively. The company attributed the revision to a stronger U.S. dollar and recent challenges in China.
How is Nature’s Sunshine responding to its China and Digital business challenges?
Management said it has begun rebuilding China’s consultant leadership base and is continuing to invest in the Digital business to position it for its next phase of growth. Operational disruptions in China affected the consultant leadership base more than management initially anticipated.